Some really great & informative abstracts in #ANCA #vasculitis poster session! Incl work on thyroid disease such as ab#1433. This study confirmed the association with AAV but also showed PR3-ANCA is assoc. w/ less risk for thyroid disease. #ACR20 @RheumNow https://t.co/bMB0o8Eylo

• Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study - ACR M…

Dr Kronzer and @jeffsparks presenting on lifestyle and clinical risk factors for RA-ILD. Obesity, CRP >=10mg/L, poor function, and high education level appear to be risks. Also threshold pk/yr effect for smoking #ACR20 @rheumnow https://t.co/dM73lBLXVN

Don’t forget to look for microscopic colitis in spondyloarthritis. It’ll solve many of your unsolved questions. #ACR20 poster session @RheumNow https://t.co/M7JubMtZiB

Thinking about Dr. Fauci's forecast for a vaccine to be deployed early 2021. If/when it is offered, would you receive it? @RheumNow #ACR20

Dr Egan presents 18-month data on use of anti-IL5 therapy in 13 EGPA patients. 50% reduction in steroid dose with anti-IL5. BVAS and asthma control questionnaire improved. 12 of 13 continued anti-IL5. @rheumnow #ACR20 Abstr#1427 https://t.co/qVy7Nb3OoA

Scurvy! Corkscrew hairs. Good exam question and we may still see it in the chips & sofa crowd and other poor eating habits. Learn from sailors re eating limes=limey. So have a twist of lemon or lime in your gin &tonic. If I guessed wrong oh well! @RheumNow @CRASCRRheum #ACR20 https://t.co/c8UN3bpPHC

• https://twitter.com/ejdein1/status/1325446284367556609

Dr Giorgiutti and @Lupusreference present on prevalence of AAV in relation to silica exposure from quarries. Prevalence of GPA 2 fold higher in region with quarries vs city. Spatial association between quarries and GPA but not MPA/RLV. @rheumnow #ACR20 Abstr#1426 https://t.co/xHnOWCdXWe

Mepolizumab (anti-IL5) shown to be clinically beneficial and well-tolerated in the long-term for patients with #EGPA, with a 50% reduction in #steroid dose in the study cohort. Abs#1427 #ACR20 @RheumNow #Vasculitis https://t.co/elr6VR7447

• Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) - An …

Dr Juge @Juge_P_A reports on prevalence of subclinical RA-ILD as identified by HRCT. At mean disease duration of 13 years 18.2% of patients had subclinical RA-ILD. @rheumnow #ACR20 Abstr#1199 https://t.co/VWKFxwFfIJ

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by @RheumNow & its Faculty.

Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS

5yr DESIR cohort data estimated incidence rate of uveitis at 1.3/100p-y; over five years, uveitis was associated w/ dactylitis, biologic and sacroiliac MRI inflammation. #ABS1304 #ACR20 @RheumNow https://t.co/qmXlY7PmBB

• Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Pros…

Important thoughts- how do we actually use the biologics in practice for the rare diseases that do not have many FDA approved options? @RheumNow #ACR20 abstract 1429 https://t.co/SsYC1kF5uv